AI Drug Repurposing Market

What is the Global AI Drug Repurposing Market Size?

The Global AI Drug Repurposing Market size is estimated at USD 1.7 billion in 2026 and is expected to reach USD 9.7 billion by 2035, expanding at a CAGR of 21.1%, driven by advancements in AI-enabled target identification, real-time biomedical data analytics, integration of evidence-based drug repurposing pipelines, and the development of interoperable research IT ecosystems.

ℹ To learn more about this report – Download Your Free Sample Report Here

The AI drug repurposing market is experiencing steady growth, driven by increased adoption of machine learning in drug discovery, regulatory pressure to reduce drug development timelines, and rising public and private investment in computational drug repurposing initiatives across research and clinical environments. The market is further shaped by advancements in real-time safety and toxicity prediction, predictive drug–disease association scoring, automated biomedical literature mining, and interoperability frameworks supporting AI deployment.

Pharmaceutical companies, payers, and health IT vendors are increasingly investing in digital modernization to improve data exchange, reduce clinical trial failure rates, and enhance overall R&D productivity. The move towards automation, predictive scaling of repurposing algorithms, and smart workload splitting (initial AI screening + final wet-lab validation) is increasing adoption. Moreover, the need to operationalize national drug development strategies and the importance of sustainable evidence-based repurposing are driving digital changes in computational pharma, and AI drug repurposing has become an essential part of the future intelligent healthcare economy on a global scale.

ℹ To learn more about this report – Download Your Free Sample Report Here

The US AI Drug Repurposing Market

The US AI Drug Repurposing Market is estimated to grow to USD 732.0 million in 2026 with a compound annual growth rate of 19.8% during the forecast period.

ℹ To learn more about this report – Download Your Free Sample Report Here

The US market is characterized by the presence of substantial federal funding programs such as ARPA-H, the FDA's Sentinel Initiative, and the NCATS Discovering New Therapeutic Uses program, all of which contribute to the growth of the need for AI-driven drug repurposing, real-time omics telemetry, and predictive repurposing success models. AI repurposing software and knowledge graph platforms continue to be adopted faster within the region, with the US requiring advanced interoperability frameworks, real-world evidence integration, and verifiable clinical AI assurance. Also, service providers are being pressured by initiatives like the 21st Century Cures Act and national AI in healthcare strategies to create dedicated integration and deployment services to guarantee data interoperability, security, and compliance across a variety of pharmaceutical and academic repurposing ecosystems.

Europe AI Drug Repurposing Market

The Europe AI Drug Repurposing Market is estimated to be valued at USD 401.2 million in 2026, witnessing growth at a CAGR of 20.3%, during the forecast period.

Europe has a mature AI drug repurposing market, and this has a significant influence on the regulatory requirements and regional policies such as the EU AI Act, the European Health Data Space (EHDS), and national digital health programs (e.g., France's Health Data Hub and Germany's Digital Healthcare Act). Countries are also striving for smart repurposing modularization to harmonize pharma and academic workload requirements and interoperability of the cross-border biomedical data supply chain. Advanced technologies, like real-time knowledge graph engines and high-reliability repurposing scoring systems with built-in predictive algorithms for toxicity, drive innovation. Public-private partnerships and harmonization of AI repurposing standards facilitate adoption. Technologies like real-time computational workload balancing and smart contract-based data sharing are commonly practiced as research-centric programs, and Europe is a frontrunner in terms of the digital transformation of safe and efficient AI drug repurposing.

Japan AI Drug Repurposing Market

The Japan AI Drug Repurposing Market is projected to be valued at USD 78.6 million in 2026, progressing at a CAGR of 20.9%, during the period spanning from 2026 to 2035.

Japan boasts a mature AI drug repurposing market supported by high-performance computational biology, diagnostic imaging integration technology, and a wide network of robotic healthcare AI innovations. Automation, precision, and clinical integrity are the priorities in the country and are achieved by predictive repurposing logic wear models and intelligent power management systems for AI repurposing assets. Growth is stimulated by government actions under the Society 5.0 initiative and constant investment in digital health infrastructure. The high volume of aging population care, chronic disease management, and pharma automation requires efficient AI repurposing for real-time evidence-based inference. The difficulties are high validation costs for new repurposing logic architectures and integration with legacy drug discovery systems, yet the prospects are in exporting developed AI repurposing technologies to Asian and Pacific markets.

Key Takeaways

• Market Size & Forecast: The Global AI Drug Repurposing Market is estimated to be valued at USD 1.7 billion in 2026 and is expected to grow to USD 9.7 billion by 2035.
• Growth Rate & Outlook: The market is expected to witness growth at a compound annual growth rate of 21.1% in the forecast period.
• Primary Growth Drivers: Technological progress in machine learning-based drug-disease association scoring and real-time evidence-based inference, regulatory requirements for faster drug development and lower costs, and pharmaceutical deployment of intelligent repurposing platforms are some of the key drivers of growth in the market.
• Key Market Trends: The use of predictive repurposing success management, real-time knowledge graph optimization, and transition to cloud-based AI telemetry and fleet management systems are some of the primary market trends.
• By Component: The Software & Platforms segment is anticipated to get the majority share of the AI drug repurposing market in 2026.
• By Technology: The Machine Learning / Deep Learning segment is expected to occupy the largest revenue share in 2026 in the AI drug repurposing market.
• By Therapeutic Area: The oncology segment is expected to get the largest revenue share in 2026 in the AI drug repurposing market.
• Regional Leadership: North America is predicted to dominate the market with an estimated 51.2% share in 2026, with high pharmaceutical R&D spend and AI drug discovery investment.

What is AI Drug Repurposing?

AI drug repurposing is a specialized computational application that mimics evidence-based biomedical reasoning to assist researchers in identifying new therapeutic uses for existing drugs, predicting drug-disease associations, and real-time safety monitoring. It employs knowledge graphs, machine learning algorithms, clinical guidelines, and real-time multi-omics data integration to provide high-accuracy predictions and extreme workflow efficiency. The contemporary systems have real-time telemetry, FHIR-based interoperability, and AI-assisted confidence scoring to ensure transparency, efficiency, and clinical reliability. These AI repurposing platforms are capable of supporting efficient drug discovery workflows, sustainable evidence-based repurposing operations, and help direct the funds of pharma, government, and research stakeholders towards scalable, long-period health IT infrastructure. They also facilitate accountability by making sure that repurposing performance data is quantified, tracked, and in line with global drug development objectives.

Use Cases

• Drug-Disease Association Scoring: AI repurposing supports real-time drug-disease interaction prediction, safety alerts, and dosing guidance with sub-second latency, reducing preclinical failure rates by orders of magnitude compared to manual literature review.
• Repurposing Success Prediction Modeling (R&D Risk): Biomedical data, including cumulative predicted efficacy per compound and validation costs, is modeled to provide workflow adjustments and continue safe operation without disruption to maintain operational stability and researcher trust.
• Real-Time Toxicity & Safety Prediction: Pharmaceutical deployments are employing knowledge graph and machine learning repurposing accelerators to perform on-device adverse event prediction, off-target interaction suggestion, and anomaly detection with quantifiable and proven accuracy.
• Population Health & Government Programs: More efficient AI repurposing contributes to the success of pandemic preparedness, rare disease treatment identification, and smart clinical surveillance, facilitate national health adoption, contribute to deployment reliability, and help implement policies, such as the clinical AI governance policy and drug repurposing policy.

How AI Is Transforming the Global AI Drug Repurposing Market?

Artificial intelligence is transforming drug repurposing by enabling predictive modeling of repurposing success probability, automatic identification of anomalies in biomedical logic performance data, and real-time optimization of prediction thresholds per therapeutic context. Telemetry and multi-omics data can be analyzed with AI algorithms to determine any degradation or performance drift and scale-optimize repurposing outcomes. This saves time, is verifiable and cheaper than manual data analysis.

Moreover, AI enhances clinical assurance through offering adaptive computational event-based scheduling, anticipating workflow threats to repurposing logic, and intelligent prioritization of AI module health monitoring. It is also involved in reducing the cost of baseline testing and ongoing performance tracking, allowing pharma IT operators to reduce the cost and physical footprint of on-prem test campaigns and improve the reliability of AI repurposing workloads and their financial returns.

Market Dynamics

Key Drivers of the Global AI Drug Repurposing Market

Rapid developments in Machine Learning and Real-Time Biomedical Inference
The market is being pushed by a fast uptake of AI-driven drug-disease association scoring, high-efficiency knowledge graph processing units, FHIR-based interoperability, and real-time telemetry analytics. These technologies will allow monitoring of the health of AI repurposing modules in real-time, identify performance anomalies early, predict repurposing success rates, and simplify the process of computational validation. Consequently, operational uptime and inference efficiency are highly enhanced as well as minimizing the expenses of manual telemetry analysis. The growth of machine learning models for target discovery, in particular, is also accelerating the need for intelligent AI repurposing, as pharma operators are more inclined towards automation and workflow optimization based on biomedical data.

Growing Focus on Drug Development Regulation and Sustainable Healthcare
The world is becoming more and more involved in policies of clinical AI safety, with governments and international bodies proposing drug development efficiency policies, like the EU AI Act's clinical evidence provisions and the US FDA's AI/ML-based Software as a Medical Device action plan. These structures are driving a high demand for efficient AI repurposing that can be used to perform ultra-low-latency inference and continuous learning. In parallel, global initiatives such as the WHO's medicines safety programs are encouraging the adoption of evidence-based repurposing architectures. The increasing calls for transparency in AI drug discovery and reduction in R&D costs are also enhancing the necessity of verifiable and safe AI repurposing in both public and private healthcare systems.

Restraints in the Global AI Drug Repurposing Market

High Costs of Integration and Computational Validation
Developing AI-based repurposing methods requires curated biomedical, chemical, and clinical data, computational-biology expertise, and laboratory or clinical studies to validate predicted candidates.

Limited Standardization Across Biomedical Data and Workflows
The industry continues to rely on multiple AI repurposing architectures, including knowledge graph-based, ML-based, NLP-based, and generative AI-based systems. However, the lack of standardized biomedical data interfaces beyond platforms like OMOP and FHIR remains a key challenge. AI repurposing lacks universal plug-and-play standards compared to traditional drug discovery modules, making integration complex and limiting interoperability of repurposing logic models.

Growth Opportunities in the Global AI Drug Repurposing Market

Expansion of Emerging Pharma R&D Programs
Developing pharmaceutical markets such as Brazil, Indonesia, Nigeria, the UAE, and Vietnam are investing in digital health infrastructure and advanced AI repurposing capabilities. These regions present strong growth potential due to increasing demand for automated drug discovery, safety prediction, and rare disease applications. With limited legacy drug discovery infrastructure, they provide opportunities for the deployment of modern AI repurposing optimized for academic and pharma environments.

Rising Demand for Cloud-Based AI Repurposing Deployment

Cloud-based AI repurposing tools can give biotechnology firms, CROs, and academic groups access to scalable computing and shared analytical workflows without requiring them to build all the infrastructure themselves. Adoption depends on privacy controls, reliable data access, model validation, and the ability to connect computational findings with laboratory research.

Global AI Drug Repurposing Market Trends

Predictive Repurposing Success Monitoring and Computational Analytics
AI repurposing platforms are being monitored and computational logic anomalies are detected in real time, and prediction override patterns are predicted using on-system learning. The use of digital twin models and machine learning algorithms is enhancing computational workflow scheduling, system lifespan, and deployment reliability. This shift is transforming AI repurposing management from manual candidate review to a fully automated, continuously optimized system monitoring.

Cloud-Based Telemetry and Fleet Management Systems
Cloud computing and digital twin technologies are taking centre stage in the operations of AI repurposing clusters. These platforms enable real-time storage and analysis of biomedical performance data, centralized fleet management, and remote monitoring of AI module health. Cloud-based systems enhance transparency, lower on-prem infrastructure expenses, and provide quicker responses to workflow changes across research nodes, as experienced by operators of large pharma AI repurposing fleets.

Research Scope and Analysis

By Component Analysis

The Software & Platforms segment is expected to remain the largest in 2026, accounting for about 52.5% of the global AI drug repurposing market, driven by its dominant use in large-scale drug discovery, seamless R&D workflow integration, and flexibility across diverse computational frameworks where real-time biomedical data access and software ecosystem maturity are essential. Meanwhile, the Services segment is witnessing strong growth, driven by rising demand for implementation, integration, and maintenance support in academic and pharma settings where customization and validation are critical. Adoption is further supported by demand for platforms that connect biomedical data sources, support reproducible candidate-ranking workflows, and fit into existing pharmaceutical and academic research processes.

By Technology Analysis

The Machine Learning / Deep Learning segment is expected to dominate in 2026, accounting for 43.9% share, driven by the central role of neural networks and predictive models in executing drug-disease association scoring and target discovery.

ℹ To learn more about this report – Download Your Free Sample Report Here

The Knowledge Graphs & Network-Based AI segment forms the second-largest category, as AI repurposing heavily relies on semantic relationships and connectivity mapping. The Generative AI & LLMs segment is witnessing the fastest growth, driven by the ability to generate novel hypotheses and summarize biomedical literature at scale.

By Drug Type Analysis

The small molecules segment is expected to dominate with around 54.2% market share in 2026, driven by the large existing pool of approved drugs, well-characterized safety profiles, and lower barriers to repurposing compared to biologics. Small molecules excel in AI repurposing scenarios due to their ability to be modeled with physicochemical properties and large historical assay data. The biologics segment, while smaller, is witnessing steady growth, driven by increasing AI applications in antibody repurposing and immunotherapy. The fusion of small molecule and biologics repurposing, with federated learning across data nodes, has the fastest development.

By Deployment Mode Analysis

The on-premise systems segment is expected to dominate with approximately 55.3% market share in 2026, reflecting pharmaceutical and research organizations’ need to control proprietary compound, assay, and research data. Cloud-based systems can offer flexible computing capacity to academic laboratories, CROs, and smaller biotechnology firms. Hybrid approaches may support collaboration across institutions, subject to data privacy, access, and governance requirements.

By Therapeutic Area Analysis

The oncology segment is expected to hold the largest share in 2026, accounting for 33.3% of the market, driven by the critical need for new cancer therapies, large volumes of genomic data, and high drug development costs. Meanwhile, the rare diseases segment is witnessing the fastest growth, driven by the ability of AI to identify repurposing candidates for small patient populations where traditional drug development is economically unviable. The neurology and infectious diseases segments also represent significant shares, driven by high unmet medical need and pandemic preparedness initiatives.

By End-User Analysis

The pharmaceutical & biotechnology companies segment represents the largest end-user in 2026, accounting for 49.7% share, driven by complex R&D environments requiring real-time repurposing decision support. Academic & research institutes form the second-largest segment, utilizing AI repurposing for hypothesis generation and translational research. The fastest-growing area is contract research organizations (CROs), offering AI-powered repurposing services to pharma clients. Healthcare providers are emerging for off-label use identification and personalized medicine applications.

The Global AI Drug Repurposing Market Report is segmented based on the following:

By Component

• Software & Platforms
• Services

By Technology

• Machine Learning / Deep Learning
• Natural Language Processing (NLP)
• Knowledge Graphs & Network-Based AI
• Generative AI & Large Language Models (LLMs)
• Computer Vision

By Drug Type

• Small Molecules
• Biologics
• Vaccines
• Peptides
• Others

By Deployment Mode

• On-Premise
• Cloud-Based

By Therapeutic Area

• Oncology
• Neurology
• Cardiovascular Diseases
• Infectious Diseases
• Immunology
• Metabolic Disorders
• Rare Diseases
• Others

By End-User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Healthcare Providers
• Others

Regional Analysis

Leading Region in the AI Drug Repurposing Market

It is projected that North America will take the lead in the global AI drug repurposing market (by value), covering a market share of about 51.2% in the year 2026. The region's dominance is driven by strong pharma R&D workload cadence (US-based NIH and FDA programs), high AI software prices relative to other regions, a mature health IT supply chain for advanced interoperability and high-speed biomedical data exchange, and the presence of key AI vendors and computational biology labs. The widespread adoption of advanced machine learning and knowledge graph-based AI repurposing for oncology, rare diseases, and government drug development programs further strengthens North America's leading position in the market. Additionally, continuous investments in AI-enabled repurposing logic monitoring and interoperability capabilities are further reinforcing regional technological leadership.

ℹ To learn more about this report – Download Your Free Sample Report Here

Fastest-Growing Region in the AI Drug Repurposing Market

Asia-Pacific is the fastest-growing region, supported by strong digital health deployment targets (China, India, Japan), increasing pharmaceutical R&D sovereignty initiatives, rising investments in domestic AI repurposing capabilities, and growing adoption of computational drug discovery systems. The region benefits from well-established IT manufacturing capacity, increasing commercial participation, and alignment with national digital health roadmaps. Countries across the region are actively deploying AI repurposing to enhance R&D productivity-per-dollar and strengthen drug discovery infrastructure. Growing emphasis on AI repurposing R&D and structured computational logic development further accelerates market expansion in the region. Moreover, increasing government support and commercial pharma commitments are expected to sustain high growth momentum.

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• The U.K.
• France
• Italy
• Russia
• Spain
• Benelux
• Nordic
• Rest of Europe

Asia-Pacific

• China
• Japan
• South Korea
• India
• ANZ
• ASEAN
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa
• Israel
• Egypt
• Rest of MEA

Competitive Landscape

The market includes pharmaceutical companies, AI drug-discovery firms, computational biology providers, and research-focused technology companies. Competition centers on the quality of biomedical data, the strength and transparency of prediction models, therapeutic-area expertise, integration with R&D workflows, and evidence that predicted candidates can progress to experimental testing.

Companies seek to differentiate through partnerships with drug developers, universities, CROs, and data providers. Product development focuses on combining chemical, molecular, clinical, and literature evidence to prioritize drug–target–disease relationships. Long-term competitiveness depends on reproducible results and progress from computational hypotheses to preclinical or clinical research.

Some of the prominent players in the Global AI Drug Repurposing Market are:

• Insilico Medicine Ltd.
• BenevolentAI Limited
• Recursion Pharmaceuticals, Inc.
• Atomwise, Inc.
• Healx Limited
• BioXcel Therapeutics, Inc.
• Owkin, Inc.
• BostonGene Corporation
• BioAge Labs, Inc.
• Ginkgo Bioworks Holdings, Inc.
• Melior Discovery, Inc.
• BullFrog AI Holdings, Inc.
• Euretos B.V.
• Innophore GmbH
• Delta4.ai, Inc.
• Schrödinger, Inc.
• XtalPi Holdings Limited
• Isomorphic Labs Limited
• Other Key Players

Recent Developments

• March 2026: Insilico Medicine Ltd. expanded its collaboration with Eli Lilly in a deal valued at up to USD 2.75 billion, enabling the use of its generative AI platform to identify and develop novel drug candidates across multiple diseases, significantly strengthening AI-driven drug repurposing and multi-indication targeting capabilities.
• April 2025: Healx Limited expanded its rare disease pipeline by leveraging its AI platform to identify repurposed drug candidates for underserved conditions, accelerating time-to-clinic and strengthening its focus on scalable AI-driven repurposing models.
• February 2025: XtalPi Holdings Limited raised almost USD 267 million through a share placement to accelerate its AI-driven drug discovery and repurposing capabilities, while expanding its "AI+" innovation platform for integrated pharmaceutical R&D.
• August 2024: Recursion Pharmaceuticals, Inc. announced the acquisition of Exscientia plc in an all-stock transaction valued at approximately USD 688 million, combining phenomics, generative chemistry, and automation capabilities to accelerate AI-driven drug discovery and repurposing at scale.

Report Details